All Stories

J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu in pair of phase 3 trials

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a pair of phase 3 trials.

Mar 10, 2025 - 12:38
 0
J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu in pair of phase 3 trials
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a pair of phase 3 trials.
Read More

Tags:

Previous Article

RIU launches two partnerships in Mauritius for marine conservation and youth voc...

Next Article

ADRA project - information session for veterinary pharmaceutical industry, Onlin...

Related Posts

US judge blocks Trump administration from cutting NIH grants amid ongoing litigation

US judge blocks Trump administration from cutting NIH g...

Mar 5, 2025  0

Allogene’s phase 1 lymphoma data show CAR-T could ‘leapfrog’ competition: analysts

Allogene’s phase 1 lymphoma data show CAR-T could ‘leap...

Feb 14, 2025  0

As BioMarin searches for 'clever science,' its R&D chief warns innovation could be hit by NIH fund drought

As BioMarin searches for 'clever science,' its R&D chie...

Feb 21, 2025  0